Differential gene expression identifies subgroups of renal cell carcinoma

Journal of Laboratory and Clinical Medicine

Volumn 147, Issue 5, 2006, Pages 250-267

  Skubitz, Keith M ^a,c   Zimmerman, Wolfgang ^d   Kammerer, Robert ^d,e   Pambuccian, Stefan ^b   Skubitz, Amy P N ^b  

^a Department of Medicine ^*  (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; KIDNEY; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; METABOLISM; PRINCIPAL COMPONENT ANALYSIS; QUANTITATIVE ANALYSIS; SAMPLE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRINCIPAL COMPONENT ANALYSIS; RNA, MESSENGER; RNA, NEOPLASM;

EID: 33646344690     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lab.2006.04.001     Document Type: Article

References (82)

1. Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E., et al. Cancer statistics, 2004. CA Cancer J Clin 54 1 (2004) 8-29
2. In: Walsh P.C., Retik A.B., Vaughan E.D., and Wein A.J. (Eds). Campbell's Urology. 8th ed. (2002), Saunders, Philadelphia, Penn
3. Mostfi F.K., and Davis C.J. WHO International Histological Classification of Tumors (1998), Springer, Berlin
4. Kovacs G., Akhtar M., Beckwith B.J., Bugert P., Cooper C.S., Delahunt B., et al. The Heidelberg classification of renal cell tumours. J Pathol 183 2 (1997) 131-133
5. Storkel S., Eble J.N., Adlakha K., Amin M., Blute M.L., Bostwick D.G., et al., Union Internationale Contre le Cancer (UICC), American Joint Committee on Cancer (AJCC). Classification of renal cell carcinoma. Workgroup No. 1. Cancer 80 5 (1997) 987-989
6. Reuter V.E., and Presti Jr. J.C. Contemporary approach to the classification of renal epithelial tumors. Semin Oncol 27 2 (2000) 124-137
7. Latif F., Tory K., Gnarra J., Yao M., Duh F.M., Orcutt M.L., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260 5112 (1993) 1317-1320
8. Semenza J.C., Ziogas A., Largent J., Peel D., and Anton-Culver H. Gene-environment interactions in renal cell carcinoma. Am J Epidemiol 153 9 (2001) 851-859
9. Atzpodien J., Kirchner H., Jonas U., Bergmann L., Schott H., Heynemann H., et al. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma. a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22 7 (2004) 1188-1194
10. Coppin C., Porzsolt F., Awa A., Kumpf J., Coldman A., and Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 1 (2005) CD001425
11. Dutcher J.P. Interleukin-2 based therapy for kidney cancer. Cancer Treat Res 116 (2003) 155-172
12. Negrier S. Better survival with interleukin-2-based regimens? Possibly only in highly selected patients. J Clin Oncol 22 7 (2004) 1174-1176
13. Vogelzang N.J., and Stadler W.M. Kidney cancer. Lancet 352 9141 (1998) 1691-1696
14. Dexeus F.H., Logothetis C.J., Sella A., Amato R., Kilbourn R., Ogden S., et al. Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma. J Urol 146 3 (1991) 709-713
15. Damascelli B., Marchiano A., Frigerio L.F., Salvetti M., Spreafico C., Garbagnati F., et al. Flexibility and efficacy of automatic continuous fluorodeoxyuridine infusion in metastases from a renal cell carcinoma. Cancer 68 5 (1991) 995-998
16. Conroy T., Geoffrois L., Guillemin F., Luporsi E., Krakowski I., Spaeth D., et al. Simplified chronomodulated continuous infusion of floxuridine in patients with metastatic renal cell carcinoma. Cancer 72 7 (1993) 2190-2197
17. Hrushesky W.J., von Roemeling R., Lanning R.M., and Rabatin J.T. Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma. J Clin Oncol 8 9 (1990) 1504-1513
18. Wilkinson M.J., Frye J.W., Small E.J., Venook A.P., Carroll P.R., Ernest M.L., et al. A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma. Cancer 71 11 (1993) 3601-3604
19. Vogelzang N.J. Future directions for gemcitabine in the treatment of genitourinary cancer. Semin Oncol 29 1 Suppl 3 (2002) S40-S45
20. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumours. Nature 406 6797 (2000) 747-752
21. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 6769 (2000) 503-511
22. Khan J., Wei J.S., Ringner M., Saal L.H., Ladanyi M., Westermann F., et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 7 6 (2001) 673-679
23. Skubitz K.M., and Skubitz A.P. Differential gene expression in renal-cell cancer. J Lab Clin Med 140 1 (2002) 52-64
24. Skubitz K.M., and Skubitz A.P. Differential gene expression in leiomyosarcoma. Cancer 98 5 (2003) 1029-1038
25. Skubitz K.M., and Skubitz A.P. Characterization of sarcomas by means of gene expression. J Lab Clin Med 144 2 (2004) 78-91
26. Skubitz K.M., and Skubitz A.P. Gene expression in aggressive fibromatosis. J Lab Clin Med 143 2 (2004) 89-98
27. Hedenfalk I., Duggan D., Chen Y., Radmacher M., Bittner M., Simon R., et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 344 8 (2001) 539-548
28. Nielsen T.O., West R.B., Linn S.C., Alter O., Knowling M.A., O'Connell J.X., et al. Molecular characterisation of soft tissue tumours. a gene expression study. Lancet 359 9314 (2002) 1301-1307
29. Segal N.H., Pavlidis P., Antonescu C.R., Maki R.G., Noble W.S., DeSantis D., et al. Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol 163 2 (2003) 691-700
30. Young A.N., Amin M.B., Moreno C.S., Lim S.D., Cohen C., Petros J.A., et al. Expression profiling of renal epithelial neoplasms. a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol 158 5 (2001) 1639-1651
31. Takahashi M., Rhodes D.R., Furge K.A., Kanayama H., Kagawa S., Haab B.B., et al. Gene expression profiling of clear cell renal cell carcinoma. gene identification and prognostic classification. Proc Natl Acad Sci USA 98 17 (2001) 9754-9759
32. Takahashi M., Yang X.J., Sugimura J., Backdahl J., Tretiakova M., Qian C.N., et al. Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene 22 43 (2003) 6810-6818
33. Higgins J.P., Shinghal R., Gill H., Reese J.H., Terris M., Cohen R.J., et al. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol 162 3 (2003) 925-932
34. Li G., Cuilleron M., Gentil-Perret A., Cottier M., Passebosc-Faure K., Lambert C., et al. Rapid and sensitive detection of messenger RNA expression for molecular differential diagnosis of renal cell carcinoma. Clin Cancer Res 9 17 (2003) 6441-6446
35. Furge K.A., Lucas K.A., Takahashi M., Sugimura J., Kort E.J., Kanayama H., et al. Robust classification of renal cell carcinoma based on gene expression data and predicted cytogenetic profiles. Cancer Res 64 12 (2004) 4117-4121
36. Gieseg M.A., Cody T., Man M.Z., Madore S.J., Rubin M.A., and Kaldjian E.P. Expression profiling of human renal carcinomas with functional taxonomic analysis. BMC Bioinformat 3 1 (2002) 26
37. Yao M., Tabuchi H., Nagashima Y., Baba M., Nakaigawa N., Ishiguro H., et al. Gene expression analysis of renal carcinoma. adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma. J Pathol 205 3 (2005) 377-387
38. Sultmann H., von Heydebreck A., Huber W., Kuner R., Buness A., Vogt M., et al. Gene expression in kidney cancer is associated with cytogenetic abnormalities, metastasis formation, and patient survival. Clin Cancer Res 11 2 Pt 1 (2005) 646-655
39. Schuetz A.N., Yin-Goen Q., Amin M.B., Moreno C.S., Cohen C., Hornsby C.D., et al. Molecular classification of renal tumors by gene expression profiling. J Mol Diagn 7 2 (2005) 206-218
40. Vasselli J.R., Shih J.H., Iyengar S.R., Maranchie J., Riss J., Worrell R., et al. Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci USA 100 12 (2003) 6958-6963
41. Amatschek S., Koenig U., Auer H., Steinlein P., Pacher M., Gruenfelder A., et al. Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res 64 3 (2004) 844-856
42. Moch H., Schraml P., Bubendorf L., Mirlacher M., Kononen J., Gasser T., et al. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol 154 4 (1999) 981-986
43. Lenburg M.E., Liou L.S., Gerry N.P., Frampton G.M., Cohen H.T., and Christman M.F. Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC Cancer 3 1 (2003) 31
44. Wang E., Lichtenfels R., Bukur J., Ngalame Y., Panelli M.C., Seliger B., et al. Ontogeny and oncogenesis balance the transcriptional profile of renal cell cancer. Cancer Res 64 20 (2004) 7279-7287
45. Boer J.M., Huber W.K., Sultmann H., Wilmer F., von Heydebreck A., Haas S., et al. Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500- element cDNA array. Genome Res 11 11 (2001) 1861-1870
46. Murphy W.M., Grignon D.J., and Perlman E.J. Tumors of the kidney, bladder, and related urinary structures. In: Silververg S.G., and Sobin L.H. (Eds). Atlas of Tumor Pathology, 4th series, fascicle 1, American Registry of Pathology Vol. 7 (2004), American Registry of Pathology, Washington, DC
47. Eble J.N., Sauter G., Epstein J.I., and Sesterhenn I.A. Pathology and genetics of tumors of the urinary system and male genital organs. World Health Organization Classification of Tumors Vol 43 (2004), IARC Press, Lyon, France
48. Lohse C.M., Blute M.L., Zincke H., Weaver A.L., and Cheville J.C. Comparison of standardized and nonstandardized nuclear grade of renal cell carcinoma to predict outcome among 2,042 patients. Am J Clin Pathol 118 6 (2002) 877-886
49. de Peralta-Venturina M., Moch H., Amin M., Tamboli P., Hailemariam S., Mihatsch M., et al. Sarcomatoid differentiation in renal cell carcinoma. a study of 101 cases. Am J Surg Pathol 25 3 (2001) 275-284
50. Cheville J.C., Lohse C.M., Zincke H., Weaver A.L., Leibovich B.C., Frank I., et al. Sarcomatoid renal cell carcinoma. an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol 28 4 (2004) 435-441
51. Sengupta S., Lohse C.M., Leibovich B.C., Frank I., Thompson R.H., Webster W.S., et al. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer 104 3 (2005) 511-520
52. Skubitz K.M., Cheng E.Y., Clohisy D.R., Thompson R.C., and Skubitz A.P. Gene expression in giant-cell tumors. J Lab Clin Med 144 4 (2004) 193-200
53. Skubitz K.M., and Skubitz A.P. Differential gene expression in uterine leiomyoma. J Lab Clin Med 141 5 (2003) 297-308
54. Kim H.L., Seligson D., Liu X., Janzen X., Bui N., Yu M.H., et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 10 16 (2004) 5464-5471
55. Motzer R.J., Bacik J., Schwartz L.H., Reuter V., Russo P., Marion S., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22 3 (2004) 454-463
56. Liou L.S., Shi T., Duan Z.H., Sadhukhan P., Der S.D., Novick A.A., et al. Microarray gene expression profiling and analysis in renal cell carcinoma. BMC Urol 4 1 (2004) 9
57. Ivanov S.V., Kuzmin I., Wei M.H., Pack S., Geil L., Johnson B.E., et al. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci USA 95 21 (1998) 12596-12601
58. Rae F.K., Stephenson S.A., Nicol D.L., and Clements J.A. Novel association of a diverse range of genes with renal cell carcinoma as identified by differential display. Int J Cancer 88 5 (2000) 726-732
59. Thrash-Bingham C.A., and Tartof K.D. aHIF. a natural antisense transcript overexpressed in human renal cancer and during hypoxia. J Natl Cancer Inst 91 2 (1999) 143-151
60. Stassar M.J., Pitzer C., and Zoller M. Downregulation of TNF receptor-associated protein-2/p97 in renal cell carcinoma. Oncol Res 11 2 (1999) 85-90
61. Kocher O., Cheresh P., Brown L.F., and Lee S.W. Identification of a novel gene, selectively up-regulated in human carcinomas, using the differential display technique. Clin Cancer Res 1 10 (1995) 1209-1215
62. Nishie A., Masuda K., Otsubo M., Migita T., Tsuneyoshi M., Kohno K., et al. High expression of the Cap43 gene in infiltrating macrophages of human renal cell carcinomas. Clin Cancer Res 7 7 (2001) 2145-2151
63. Paradis V., Bieche I., Dargere D., Bonvoust F., Ferlicot S., Olivi M., et al. hTERT expression in sporadic renal cell carcinomas. J Pathol 195 2 (2001) 209-217
64. Lohi J., Leivo I., Oivula J., Lehto V.P., and Virtanen I. Extracellular matrix in renal cell carcinomas. Histol Histopathol 13 3 (1998) 785-796
65. Hagemann T., Gunawan B., Schulz M., Fuzesi L., and Binder C. mRNA expression of matrix metalloproteases and their inhibitors differs in subtypes of renal cell carcinomas. Eur J Cancer 37 15 (2001) 1839-1846
66. Bui M.H., Seligson D., Han K.R., Pantuck A., Dorey F., Huang Y., et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma. implications for prognosis and therapy. Clin Cancer Res 9 2 (2003) 802-811
67. Grabmaier K., Vissers J.L., De Weijert M.C., Oosterwijk-Wakka J.C., Van Bokhoven A., Brakenhoff R.H., et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer 85 6 (2000) 865-870
68. Wiesener M.S., Munchenhagen P.M., Berger I., Morgan N.V., Roigas J., Schwiertz A., et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res 61 13 (2001) 5215-5222
69. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D., Topalian S.L., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 5 (2003) 427-434
70. Lal A., Peters H., St Croix B., Haroon Z.A., Dewhirst M.W., Strausberg R.L., et al. Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 93 17 (2001) 1337-1343
71. Mukouyama H., Janzen N.K., Hernandez J.M., Lam J.S., Caliliw R., Wang A.Y., et al. Generation of kidney cancer-specific antitumor immune responses using peripheral blood monocytes transduced with a recombinant adenovirus encoding carbonic anhydrase 9. Clin Cancer Res 10 4 (2004) 1421-1429
72. Pantuck A.J., Zeng G., Belldegrun A.S., and Figlin R.A. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma. exploiting the hypoxia-induced pathway. Clin Cancer Res 9 13 (2003) 4641-4652
73. Oosterwijk E., Debruyne F.M., and Schalken J.A. The use of monoclonal antibody G250 in the therapy of renal-cell carcinoma. Semin Oncol 22 1 (1995) 34-41
74. Ivanov S., Liao S.Y., Ivanova A., Danilkovitch-Miagkova A., Tarasova N., Weirich G., et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158 3 (2001) 905-919
75. Sherief M.H., Low S.H., Miura M., Kudo N., Novick A.C., and Weimbs T. Matrix metalloproteinase activity in urine of patients with renal cell carcinoma leads to degradation of extracellular matrix proteins. possible use as a screening assay. J Urol 169 4 (2003) 1530-1534
76. Daniel L., Bouvier C., Chetaille B., Gouvernet J., Luccioni A., Rossi D., et al. Neural cell adhesion molecule expression in renal cell carcinomas. relation to metastatic behavior. Hum Pathol 34 6 (2003) 528-532
77. Lieubeau-Teillet B., Rak J., Jothy S., Iliopoulos O., Kaelin W., and Kerbel R.S. von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Res 58 21 (1998) 4957-4962
78. Bluyssen H.A., Lolkema M.P., van Beest M., Boone M., Snijckers C.M., Los M., et al. Fibronectin is a hypoxia-independent target of the tumor suppressor VHL. FEBS Lett 556 1-3 (2004) 137-142
79. Kruger T., Schoor O., Lemmel C., Kraemer B., Reichle C., Dengjel J., et al. Lessons to be learned from primary renal cell carcinomas. novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol Immunother 54 9 (2006) 826-836
80. Epstein A.C., Gleadle J.M., McNeill L.A., Hewitson K.S., O'Rourke J., Mole D.R., et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107 1 (2001) 43-54
81. Furuya M., Nishiyama M., Kimura S., Suyama T., Naya Y., Ito H., et al. Expression of regulator of G protein signalling protein 5 (RGS5) in the tumour vasculature of human renal cell carcinoma. J Pathol 203 1 (2004) 551-558
82. Shi T., Dong F., Liou L.S., Duan Z.H., Novick A.C., and DiDonato J.A. Differential protein profiling in renal-cell carcinoma. Mol Carcinog 40 1 (2004) 47-61